Stroke Clinical Trial
— RIISC-THETISOfficial title:
Reducing Inflammation in Ischemic Stroke With Colchicine, and Ticagrelor in High-risk Patients-extended Treatment in Ischemic Stroke
REDUCING INFLAMMATION IN ISCHEMIC STROKE WITH COLCHICINE, AND TICAGRELOR IN HIGH-RISK PATIENTS-EXTENDED TREATMENT IN ISCHEMIC STROKE.
Status | Recruiting |
Enrollment | 2800 |
Est. completion date | September 1, 2027 |
Est. primary completion date | September 1, 2027 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion criteria: Patient should have the following: Patient with: 1. Cerebral infarction (CI) proven by neuro-imaging (MRI or head-CT), immediately once the neurologic deficit is stabilized (investigator judgement) if the patient was on antiplatelet agent monotherapy after the qualifying event, or after 21 days if the patient was on clopidogrel plus aspirin after the qualifying event, or after 21 to 30 days if the patient was on ticagrelor plus aspirin after the qualifying event (TIA with documented ischemic lesion (MRI or CT) in the appropriate area corresponding to the symptoms will be considered CI, following the current definition) 2. Or TIA lasting more 10 minutes or more (with motor symptoms or aphasia/dysarthria or visual defect), with total resolution and no brain lesion on neuro-imaging (TIA) and with ipsilateral carotid stenosis that was revascularized (endarterectomy or stenting) or with ipsilateral, potentially causal intracranial stenosis =70%) if the patient was on antiplatelet agent monotherapy after the qualifying event, or after 21 days if the patient was on clopidogrel plus aspirin after the qualifying event, or after 21 to 30 days if the patient was on ticagrelor plus aspirin after the qualifying event 3. and documented atherosclerotic stenosis: 1. presence of carotid atherosclerotic stenosis (on the basis of carotid duplex, CTA, MRA, XRA - only the report will be required to document atherosclerotic disease) ipsilateral to the cerebral ischemic symptoms (stenosis defined by luminal narrowing =30%, judgement of the investigator) 2. or presence of atherosclerotic stenosis of another cerebral artery (documented vertebral artery stenosis, basilar artery stenosis, other intracranial artery stenosis) ipsilateral to the ischemic area (stenosis defined by luminal narrowing =30%, judgement of the investigator) 3. or presence of atherosclerotic disease of the aortic arch with a plaque =4mm in thickness with or without superimposed thrombus, or a plaque <4 mm with a superimposed mobile thrombus (detected by transesophageal echocardiography or CT angiography) 4. with no clear indication of colchicine treatment (gout, Mediterranean fever) and with an indication to long-term antiplatelet therapy (no clear indication to oral anticoagulant) 5. age equal or above 18 6. Rankin score less than =4 (ranges from 0 to 6, with 0 indicating no symptoms, 1 no disability, 2 to 3 needing some help with daily activities, 4 to 5 dependent or bedridden, and 6 death), 7. fully informed and signed inform consent 8. with social security number. 9. medical examination before the participation to the research 10. Under contraception in case of childbearing potential (highly effective: 1) combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation et 2) progestogen-only). 11. Pregnancy test for women of childbearing potential Exclusion Criteria: 1. Colchicine treatment needed (e.g., gout, Mediterranean fever) 2. Hypersensitivity to ticagrelor or any of the excipients. 3. Hypersensitivity to colchicine or any of the excipients. 4. Major digestive disorders (chronic diarrhea, inflammatory disease of the digestive tract as uncontrolled ulcerative colitis or active Crohn disease) 5. Immunosuppression, medullary aplasia 6. Active chronic inflammatory disease, chronic active infection, evolving cancer 7. Hemodynamic instability (need for amines for more than 24 hours, circulatory assistance) 8. A recent severe sepsis (7 days) or all recent acute reaches 9. Chronic treatment (for more than 6 months) with corticosteroids or NSAIDs (or repeated high-dose intake for less than 7 days). 10. Anticipated concomitant oral or intravenous therapy with strong CYP3A4 inhibitors or CYP3A4 substrates than cannot be stopped for the course of the course of this study 11. CI/TIA due to arterial dissection (as documented following the judgment of the investigator) or due to cardiac source of embolism without documented atherosclerotic disease (e.g., mitral stenosis or endomyocardial fibrosis, endocarditis) a patient with atrial fibrillation, or with a history of myocardial infarction, or with calcified aortic stenosis will be eligible if the above inclusion criteria are also met] 12. Indication to long-term oral anticoagulant treatment (e.g., atrial fibrillation) 13. Symptomatic hemorrhagic stroke (the mere presence of asymptomatic cerebral hemosiderin deposits -so called "microbleedings" - on gradient echo imaging is not an exclusion criteria) 14. Active pathological bleeding 15. Uncontrolled hypertension (investigator judgement) 16. Follow-up visit impossible or anticipated bad compliance. 17. Intercurrent disease that may interfere with evaluation of the primary end-point or that may prevent follow-up study visits.. 18. Anticipated pregnancy at time of enrollment in the study 19. Breastfeeding woman 20. Patients participating in another pharmaco therapeutic program with an experimental therapy that is known to affect the ticagrerlor, colchicine or aspirine therapy. 21. Leukopenia <3000/µl 22. Patients with severe renal impairment (creatinine clearance < 30 ml/min) 23. Patients with severe hepatic impairment 24. Prohibited treatments: All treatments contraindicated during the use of colchicine and/or ticagrelor |
Country | Name | City | State |
---|---|---|---|
France | URC Lariboisière-Fernand Widal-Saint Louis | Paris |
Lead Sponsor | Collaborator |
---|---|
Assistance Publique - Hôpitaux de Paris |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants with nonfatal ischemic stroke | Sudden onset of focal neurologic symptoms related to impaired cerebral circulation. ASCOD phenotyping will be used. TIAs will not be part of strokes. However, any focal neurologic symptoms associated with positive DWI or hypodensity on the CT scan in an appropriate area in relation with these symptoms will be considered a cerebral infarction and be part of "strokes". | 36 months | |
Primary | Number of Participants with undetermined stroke | Sudden onset of focal neurologic symptoms related to impaired cerebral circulation. ASCOD phenotyping will be used. TIAs will not be part of strokes. However, any focal neurologic symptoms associated with positive DWI or hypodensity on the CT scan in an appropriate area in relation with these symptoms will be considered a cerebral infarction and be part of "strokes". | 36 months | |
Primary | Number of Participants with nonfatal myocardial infarction | Fatal or nonfatal myocardial infarction (OMS.AHA/ACC definition)
o Clinical symptoms + elevated troponin Silent myocardial infarction following universal definition |
36 months | |
Primary | Number of Participants with urgent coronary or carotid revascularization following new symptoms | Revascularization Procedure
Coronary : Angioplasty or stenting or CABG Carotid : angioplasty or stenting, surgical endarterectomy Peripheral: angioplasty or stenting including aorta, surgical by-pass or endarterectomy of a peripheral artery. |
36 months | |
Primary | Number of Participants with vascular death including sudden death | - Vascular death
Death due to cardiac or vascular cause Death due to systemic hemorrhage Death due to pulmonary embolism Sudden death: death occurring within 24 hours, unexpected in a patient in apparent healthy condition or condition that was stable or improved Death without documented nonvascular cause Fatal stroke: death occurring within 30 days of stroke onset (whether ischemic or hemorrhagic). |
36 months | |
Secondary | Number of Participants with recurrent fatal and nonfatal ischemic stroke | 36 months | ||
Secondary | Number of Participants with urgent carotid revascularization following a new transient ischemic attack with negative neuro-imaging | 36 months | ||
Secondary | Number of Participants with fatal and nonfatal myocardial infarction | 36 months | ||
Secondary | Number of Participants with fatal and nonfatal myocardial infarction or urgent coronary revascularization following a new acute coronary syndrome | 36 months | ||
Secondary | Number of Participants with vascular death | 36 months | ||
Secondary | Number of Participants with any stroke or TIA | A TIA is defined by sudden onset of neurologic symptoms presumed of ischemic origin, with total resolution, being clearly related to focal cerebral or retinal involvement, and with negative neuro-imaging in the cerebral area corresponding to the symptoms. TIA diagnosis must be confirmed by a neurologist, based on clinical and negative neuro-imaging evaluation (MRI with DWI is recommended). | 36 months | |
Secondary | Number of Participants with major coronary events | 36 months | ||
Secondary | Number of Participants with any coronary end-points (MI, hospitalization for recurrent ACS, coronary revascularization procedure urgent or elective, fatal coronary event) | ACS: Acute Coronary Syndrome | 36 months | |
Secondary | Number of death participant (any death) | 36 months | ||
Secondary | Number of Participant with all revascularization procedures (coronary, carotid, peripheral) | 36 months | ||
Secondary | Number of Participants with Carotid revascularization | 36 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04043052 -
Mobile Technologies and Post-stroke Depression
|
N/A | |
Recruiting |
NCT03869138 -
Alternative Therapies for Improving Physical Function in Individuals With Stroke
|
N/A | |
Completed |
NCT04034069 -
Effects of Priming Intermittent Theta Burst Stimulation on Upper Limb Motor Recovery After Stroke: A Randomized Controlled Trial
|
N/A | |
Completed |
NCT04101695 -
Hemodynamic Response of Anodal Transcranial Direct Current Stimulation Over the Cerebellar Hemisphere in Healthy Subjects
|
N/A | |
Terminated |
NCT03052712 -
Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies
|
N/A | |
Completed |
NCT00391378 -
Cerebral Lesions and Outcome After Cardiac Surgery (CLOCS)
|
N/A | |
Recruiting |
NCT06204744 -
Home-based Arm and Hand Exercise Program for Stroke: A Multisite Trial
|
N/A | |
Active, not recruiting |
NCT06043167 -
Clinimetric Application of FOUR Scale as in Treatment and Rehabilitation of Patients With Acute Cerebral Injury
|
||
Active, not recruiting |
NCT04535479 -
Dry Needling for Spasticity in Stroke
|
N/A | |
Completed |
NCT03985761 -
Utilizing Gaming Mechanics to Optimize Telerehabilitation Adherence in Persons With Stroke
|
N/A | |
Recruiting |
NCT00859885 -
International PFO Consortium
|
N/A | |
Recruiting |
NCT06034119 -
Effects of Voluntary Adjustments During Walking in Participants Post-stroke
|
N/A | |
Completed |
NCT03622411 -
Tablet-based Aphasia Therapy in the Chronic Phase
|
N/A | |
Completed |
NCT01662960 -
Visual Feedback Therapy for Treating Individuals With Hemiparesis Following Stroke
|
N/A | |
Recruiting |
NCT05854485 -
Robot-Aided Assessment and Rehabilitation of Upper Extremity Function After Stroke
|
N/A | |
Active, not recruiting |
NCT05520528 -
Impact of Group Participation on Adults With Aphasia
|
N/A | |
Completed |
NCT03366129 -
Blood-Brain Barrier Disruption in People With White Matter Hyperintensities Who Have Had a Stroke
|
||
Completed |
NCT05805748 -
Serious Game Therapy in Neglect Patients
|
N/A | |
Completed |
NCT03281590 -
Stroke and Cerebrovascular Diseases Registry
|
||
Recruiting |
NCT05621980 -
Finger Movement Training After Stroke
|
N/A |